Literature DB >> 15289241

Impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer.

J W B de Groot1, Th P Links, P L Jager, T Kahraman, J Th M Plukker.   

Abstract

BACKGROUND: Conventional imaging such as with (99m)Tc(V)dimercaptosunnic acid (DMSA), (111)In-octreotide scintigraphy, computed tomography (CT), and magnetic resonance imaging (MRI) rarely localizes occult medullary thyroid cancer (MTC). The role of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) is not well defined. The aim of this study was to examine the usefulness of postoperative FDG-PET in localizing MTC metastases.
METHODS: FDG-PET was performed in 26 patients with elevated serum tumor markers after total thyroidectomy with central compartment dissection and additional neck dissection on indication. Patient- and lesion-based results were compared with the findings of conventional nuclear imaging and validated by morphological imaging (CT, MRI, ultrasonography), including bone scintigraphy and pathology when possible. Clinical impact was evaluated.
RESULTS: FDG-PET detected foci in 50% of patients with lesion-based sensitivity of 96%. (111)In-octreotide detected foci in 19% with sensitivity of 41%, and (99m)Tc(V)DMSA scintigraphy and morphological imaging detected foci in 21% and 40%, respectively, with sensitivity of 57% and 87%. No lesions were found in 11 patients (42%). Positive FDG-PET findings led to surgical intervention in nine patients (35%). They all underwent surgery for removal of residual tumor or metastases. One patient achieved disease-free status. In all patients who underwent surgery, serum calcitonin levels were reduced by an average of 58 +/- 31%.
CONCLUSIONS: For detection of occult MTC lesions, FDG-PET is superior to conventional nuclear imaging and is the best detection method yet available. FDG-PET in postoperative follow-up has clinical value and may be used for guiding reoperation and additional morphological imaging preoperatively.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15289241     DOI: 10.1245/ASO.2004.10.015

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  21 in total

Review 1.  Medullary thyroid cancer: monitoring and therapy.

Authors:  Douglas W Ball
Journal:  Endocrinol Metab Clin North Am       Date:  2007-09       Impact factor: 4.741

2.  The prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose positron emission tomography in patients with suspected residual or recurrent medullary thyroid carcinoma.

Authors:  Trond Velde Bogsrud; Dimitrios Karantanis; Mark A Nathan; Brian P Mullan; Gregory A Wiseman; Jan L Kasperbauer; Carl C Reading; Trine Björo; Ian D Hay; Val J Lowe
Journal:  Mol Imaging Biol       Date:  2009-12-01       Impact factor: 3.488

3.  Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D-glucose-PET and PET/CT.

Authors:  Andrei Iagaru; Rinat Masamed; Peter A Singer; Peter S Conti
Journal:  Mol Imaging Biol       Date:  2007 Mar-Apr       Impact factor: 3.488

4.  Comparison of (68)Ga-DOTATATE and (18)F-fluorodeoxyglucose PET/CT in the detection of recurrent medullary thyroid carcinoma.

Authors:  Brendon G Conry; Nikolaos D Papathanasiou; Vineet Prakash; Irfan Kayani; Martyn Caplin; Shahid Mahmood; Jamshed B Bomanji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

Review 5.  Molecular imaging of neuroendocrine tumors.

Authors:  Jorge A Carrasquillo; Clara C Chen
Journal:  Semin Oncol       Date:  2010-12       Impact factor: 4.929

6.  Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.

Authors:  B Beuthien-Baumann; A Strumpf; J Zessin; J Bredow; J Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-04-14       Impact factor: 9.236

7.  An analysis of the utility of handheld PET probes for the intraoperative localization of malignant tissue.

Authors:  Segundo Jaime González; Lorena González; Joyce Wong; Peter Brader; Maureen Zakowski; Mithat Gönen; Farhad Daghighian; Yuman Fong; Vivian E Strong
Journal:  J Gastrointest Surg       Date:  2010-11-25       Impact factor: 3.452

8.  Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma.

Authors:  Giorgio Treglia; Paola Castaldi; Maria Felicia Villani; Germano Perotti; Chiara de Waure; Angelina Filice; Valentina Ambrosini; Nadia Cremonini; Monica Santimaria; Annibale Versari; Stefano Fanti; Alessandro Giordano; Vittoria Rufini
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-06       Impact factor: 9.236

Review 9.  Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis.

Authors:  Giorgio Treglia; Maria Felicia Villani; Alessandro Giordano; Vittoria Rufini
Journal:  Endocrine       Date:  2012-04-17       Impact factor: 3.633

10.  Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma.

Authors:  Rafał Czepczyński; Maria Gemma Parisella; Jerzy Kosowicz; Renata Mikołajczak; Katarzyna Ziemnicka; Maria Gryczyńska; Jerzy Sowiński; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-05-26       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.